# Trade Mark Journal No.2026/007 13 February 2026

## UK00004331475 28 January 2026 (5,42)

International priority date claimed: 13 August 2025 (United States of America) (99334700)

Class 5
  Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and related diseases and disorders.
Class 42
  Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology.

Avidity Biosciences, Inc.

Representative: Abion UK Limited